WIN Invests in iLoF and Expands Its Portfolio with a Deeptech Company at the Intersection of Healthcare, Biotechnology, and AI

„WEBIT INVESTMENT NETWORK" AD (WIN), an investment company whose shares are admitted to trading on the SME Growth Market BEAM, organized and maintained by the Bulgarian Stock Exchange, announces a new investment in iLoF – Intelligent Lab on Fiber Limited (United Kingdom) — a deeptech company developing a platform for biological sample analysis through a combination of photonics and artificial intelligence.

The iLoF platform generates unique biological "fingerprints" — molecular profiles extracted from biological fluids at high speed and without destroying the sample. Its primary applications are in pre-clinical analytics and the biopharma sector, with a clear technological pathway toward clinical diagnostics and accelerating therapy development.

Traction and Validation: The Numbers Speak

iLoF recorded revenue growth of over 40% in 2025 compared to the previous year — a signal of real market pull, not merely technological potential. The company works with AstraZeneca, Johnson & Johnson and Hamamatsu Medical Centers, confirming the platform's practical applicability at an institutional level.

Who Are the Other Investors in iLoF

WIN joins a company backed by Microsoft Ventures (M12), Lunar Ventures, Quiet Capital, Hamamatsu and EIT Health — an investor portfolio representing institutional validation of the highest order in technology and healthcare venture.

This is where WIN's model reveals its essence. In the traditional venture model, rounds involving Microsoft M12 and funds of that caliber are accessible only to the largest global institutions — organizations managing billions. By purchasing WIN shares on the Bulgarian Stock Exchange, any investor — regardless of the size of their capital — becomes an indirect co-investor alongside these names.

Strategic Context: The Infrastructure of Biological AI

The investment in iLoF follows WIN's existing position in InHeart — a company focused on AI-based cardiological diagnostics. The two investments form a coherent strategic block: building the biological data infrastructure layer upon which the next generation of medical AI will be developed.

"AI will transform healthcare. But the real question is not when — but on whose data. InHeart and iLoF are building exactly that infrastructure. In an environment of geopolitical uncertainty and accelerating AI evolution, ownership of this layer makes our portfolio more resilient and future-proof," said Dr. Plamen Roussev, representative of the executive member of the Board of Directors of WIN — Webit Management Ltd.

WIN also announces its intention to expand its investment focus into two new verticals: defense and dual-use solutions, as well as energy and energy storage — as a foundation for the growth of AI infrastructure.

Investment Process

iLoF was identified through Founders Games — Webit's program in which thousands of companies from over 150 countries apply, with approximately 0.1% reaching the finals. The investment went through WIN's full internal process: a vote by the Investors' Council and approval by the Investment Committee.

Revenue across companies in WIN's portfolio has grown by 230% over two years, according to the latest audited report.

This press release contains information of potential significance to the price of the company's financial instruments. Full disclosures are available in the official regulatory announcements of "WEBIT INVESTMENT NETWORK" AD — x3news.com and webit.network/internalinfo.php.

Media contacts: [email protected] | www.webit.network

News